We are thrilled to share a major milestone for a long-standing member of the Frontiers Health ecosystem: Click Therapeutics.

They recently announced a strategic agreement with Boehringer Ingelheim to support the commercialization of CT-155, an investigational prescription digital therapeutic (PDT) for the treatment of negative symptoms in schizophrenia.

Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing authorization rights, to Click Therapeutics. To support this transition, Boehringer has made a $50 million Series D investment and provided dedicated commercial funding.

The Frontiers Health Connection

Click Therapeutics has been a cornerstone of our ecosystem for nearly a decade, using the Frontiers Health stage to preview the commercial and clinical milestones they are achieving today:

• #FH25: Most recently in Berlin, Click Therapeutrics participated in the panel "Innovative Modalities: Archetypes for Scalable Healthcare Transformation," discussing the very commercial models that this Series D funding will now implement. [watch now ]
• #FH24: David Benshoof Klein returned to discuss the "Intersection of Medication and Software," specifically outlining the future of "combination products" like the one now heading to market. [watch now] He also joined a panel focused on the timing of market entry for integrated treatments, the role of pharma companies in developing such solutions, and the investment landscape necessary to scale these innovations. [watch now]
• #FH20: The company focused on removing barriers to healthcare access, a mission now realized through the patient-centric design of their PDT. [watch now ]
• #FH17: CEO David Benshoof Klein delivered a keynote on targeting multiple indications with a digital therapeutics platform, laying the technical foundation for CT-155. [watch now]

DATE: 9 April 2026 | SOURCE: www.clicktherapeutics.com

Join us and our global community of health innovators in Berlin on October 20-21, 2026.

Pre-Register now!